Clinical characteristics of clear cell carcinoma of the ovary

Sugiyama, Toru; Kamura, Toshiharu; Kigawa, Junzo; Terakawa, Naoki; Kikuchi, Yoshihiro; Kita, T; Suzuki, Mitsuaki; Sato, Ikuo; Taguchi, Kouji

doi:10.1002/1097-0142(20000601)88:11<2584::aid-cncr22>3.0.co;2-5

Cited by 666 publications

(239 citation statements)

References 14 publications

Supporting

Mentioning

224

Contrasting

Order By: Relevance

“…The present study confirmed that CAP regimen showed a low response rate and quite a high incidence of PD in CCC patients as described previously (Sugiyama et al, 2000). The combination chemotherapy consisting of paclitaxel and platinum has been established as standard therapy for ovarian cancer.…”

Section: Discussionsupporting

confidence: 91%

“…Previous Japanese report have shown that the chemotherapeutic effect was assessable in only 27 patients (26.7%) in 101 CCC cases, in contrast it was assessable in 47% of serous adenocarcinoma (Sugiyama et al, 2000). In our series of CCC patients, patients with residual tumour diameter more than 1 cm were documented in only 60 (18%) of 254 cases, and the chemotherapeutic effect was assessable in only in 73 cases (29%) in 242 patients who received adjuvant chemotherapy.…”

Section: Discussioncontrasting

confidence: 59%

“…Proportion of stage I/II tumours ranged from 59 to 71% (Yoonessi et al, 1984;Crozier et al, 1989;Jenison et al, 1989;Kennedy et al, 1989;O'Brien et al, 1993;Behbakht et al, 1998;Sugiyama et al, 2000). One of the reasons for the early detection was explained by the slow growing tumour behaviour (Itamochi et al, 2002a) and frequent presentation of the tumours as relatively large pelvic masses (Kennedy et al, 1989;Behbakht et al, 1998).…”

Section: Discussionmentioning

confidence: 99%

“…To our knowledge, only a few clinical studies have evaluated the response rates for CCC patients with measurable disease. The response rate of chemotherapy for CCC was 11.1% with platinum-based regimens (Sugiyama et al, 2000) and 22 -56% with paclitaxel plus carboplatin. (Enomoto et al, 2003;Ho et al, 2004).…”

mentioning

confidence: 99%

See 3 more Smart Citations

Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging

et al. 2006

View full text Add to dashboard Cite

A retrospective analysis was performed to evaluate the clinical characteristics and prognostic factors in the patients with clear cell carcinoma (CCC) of the ovary. After central pathological review and scanning of the medical records of nine Japanese institutions between 1992 and 2003, a total of 254 patients with CCC of the ovary were enrolled in the present study. Mean age was 52.4 years (range 23 -73 years). Tumours were 13% (33/254) stage Ia, 36% (92/254) stage Ic, 13% (33/254) stage II, 30% (80/254) stage III, and 6% (16/254) stage IV. Five-year progression-free survival and overall survival was 84 and 88% in stage I, 57 and 70% in stage II, 25 and 33% in stage III and 0 and 0% in stage IV, respectively. Retroperitoneal lymph node metastasis was observed in 9% in pT1a tumours, 7% in pT1c tumours, 13% in pT2 tumours, and 58% in pT3 tumours, respectively. There was no survival benefit according to chemotherapeutic differences in the patients who received complete surgical staging procedures and conventional chemotherapy. Peritoneal cytological status was an independent prognostic factor in stage Ic patients (P ¼ 0.03) and only residual tumour diameter was an independent prognostic factor in stage III, IV patients (P ¼ 0.02). Our results suggest that cytoreductive surgery resulting in no residual tumour only could improve the prognosis of advanced CCC patients.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussioncontrasting

confidence: 59%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging

et al. 2006

View full text Add to dashboard Cite

show abstract

“…1). Of the various forms of ovarian carcinoma, the clear cell subtype has a particularly unfavorable prognosis (12). Intense myosin VI staining was observed in almost all clear cell carcinoma cases studied (Fig.…”

Section: Myosin VI Expression Is Associated With Aggressive Behavior Ofmentioning

confidence: 90%

Lessons from border cell migration in the Drosophila ovary: A role for myosin VI in dissemination of human ovarian cancer

Yoshida

Cheng

Hung

et al. 2004

Proc. Natl. Acad. Sci. U.S.A.

145

138

View full text Add to dashboard Cite

Dissemination of ovarian cancer is a major clinical challenge and is poorly understood at the molecular level due to a lack of suitable experimental models. During normal development of the Drosophila ovary, a dynamic process called border cell migration occurs that resembles the migratory behavior of human ovarian cancer cells. In this study, we found that myosin VI, a motor protein that regulates border cell migration, is abundantly expressed in high-grade ovarian carcinomas but not in normal ovary and ovarian cancers that behave indolently. Inhibiting myosin VI expression in high-grade ovarian carcinoma cells impeded cell spreading and migration in vitro. Optical imaging and histopathologic studies revealed that inhibiting myosin VI expression reduces tumor dissemination in nude mice. Therefore, using genetic analysis of border cell migration in Drosophila is a powerful approach to identify novel molecules that promote ovarian cancer dissemination and represent potential therapeutic targets.

show abstract

Uptake and Outcomes of Neoadjuvant Chemotherapy Among US Patients With Less Common Epithelial Ovarian Carcinomas

et al. 2023

View full text Add to dashboard Cite

ImportanceRandomized clinical trials examining the effectiveness of neoadjuvant chemotherapy (NACT) for advanced ovarian cancer predominantly included patients with high-grade serous carcinomas. The use and outcomes of NACT in less common epithelial carcinomas are understudied.ObjectiveTo investigate the uptake and survival outcomes in treatment with NACT for less common histologic subtypes of epithelial ovarian cancer.Design, Setting, and ParticipantsA retrospective cohort study and systematic literature review with meta-analysis was conducted using the National Cancer Database from 2006 to 2017 and the National Cancer Institute’s Surveillance, Epidemiology, and End Results Program from 2006 to 2019. Data analysis was performed from July 2022 to April 2023. The evaluation included patients with stage III to IV ovarian cancer with clear cell, mucinous, or low-grade serous histologic subtypes who received multimodal treatment with surgery and chemotherapy.ExposuresExposure assignment per the sequence of treatment: primary debulking surgery (PDS) followed by chemotherapy (PDS group) or NACT followed by interval surgery (NACT group).Main Outcomes and MeasuresTemporal trends and characteristics of NACT use were assessed using multivariable analysis, and overall survival (OS) was assessed with the inverse probability of treatment weighting propensity score.ResultsA total of 3880 patients were examined in the National Cancer Database including 1829 women (median age, 56 [IQR, 49-63] years) with clear cell, 1156 women (median age, 53 [IQR, 42-64] years) with low-grade serous, and 895 women (median age, 57 [IQR, 48-66] years) with mucinous carcinomas. NACT use increased in patients with clear cell (from 10.2% to 16.2%, 58.8% relative increase; P &lt; .001 for trend) or low-grade serous (from 7.7% to 14.2%, 84.4% relative increase; P = .007 for trend) carcinoma during the study period. This association remained consistent in multivariable analysis. NACT use also increased, but nonsignificantly, in mucinous carcinomas (from 8.6% to 13.9%, 61.6% relative increase; P = .07 for trend). Across the 3 histologic subtypes, older age and stage IV disease were independently associated with NACT use. In a propensity score–weighted model, the NACT and PDS groups had comparable OS for clear cell (4-year rates, 31.4% vs 37.7%; hazard ratio [HR], 1.12; 95% CI, 0.95-1.33) and mucinous (27.0% vs 26.7%; HR, 0.90; 95% CI, 0.68-1.19) carcinomas. For patients with low-grade serous carcinoma, NACT was associated with decreased OS compared with PDS (4-year rates, 56.4% vs 81.0%; HR, 2.12; 95% CI, 1.55-2.90). Increasing NACT use and histologic subtype–specific survival association were also found in the Surveillance, Epidemiology, and End Results Program cohort (n = 1447). A meta-analysis of 4 studies, including the current study, observed similar OS associations for clear cell (HR, 1.13; 95% CI, 0.96-1.34; 2 studies), mucinous (HR, 0.93; 95% CI, 0.71-1.21; 2 studies), and low-grade serous (HR, 2.11; 95% CI, 1.63-2.74; 3 studies) carcinomas.Conclusions and RelevanceDespite the lack of data on outcomes of NACT among patients with less common carcinomas, this study noted that NACT use for advanced disease has gradually increased in the US. Primary chemotherapy for advanced-stage, low-grade serous ovarian cancer may be associated with worse survival compared with PDS.

show abstract

Clinical characteristics of clear cell carcinoma of the ovary

Cited by 666 publications

References 14 publications

Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging

Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging

Lessons from border cell migration in the Drosophila ovary: A role for myosin VI in dissemination of human ovarian cancer

Uptake and Outcomes of Neoadjuvant Chemotherapy Among US Patients With Less Common Epithelial Ovarian Carcinomas

Contact Info

Product

Resources

About